Clinical trial
A Study of XL844 Administered as a Single Agent and in Combination With…
NCT00475917 · Exelixis, Industry · Terminated
Key facts
| NCT number | NCT00475917 |
|---|---|
| Title | A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies |
| Official title | A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Subjects With Advanced Malignancies |
| Lead sponsor | Exelixis, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer, Lymphoma |
| Intervention type | Drug |
| Interventions | XL844, Gemcitabine |
| Enrollment | 28 |
| Start date | May 1, 2007 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | May 21, 2007 |
| Last update posted | Aug 21, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: